Open an account

Alpha Tau Medical

DRTS · NASDAQ

$13.16+$0.26 (+2.02%)TodayMarket closed ·
Prev close $12.90

About DRTS

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. Company's technology relies on the diffusion of atoms that emit alpha particles within the tumor tissue, and enables alpha radiation to reach the the entire tumor. Precise amounts of radioactive radium-224 affixed that emit short-range alpha radiation enables to damages and kills cancer cells within a short period of time. The firm has one subsidiary Healthcare Capital Corp.

Employees
121
Headquarters
JERUSALEM
Listed
Mar 8, 2022
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
alphatau.com

DRTS key statistics

Market cap
1.22B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
486.51K
Volume
324.84K
Open price
$12.75
High today
$13.25
Low today
$12.70
52 Week high
$15.79
52 Week low
$3.43

Alpha Tau Medical (DRTS) at a glance

Alpha Tau Medical (DRTS) last traded at $13.16, with a market cap of 1.22B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $12.70 and $13.25. The current price is 3.6% above the day's low and 0.7% below its high.

Volume so far is 324.84K shares, below the average of 486.51K shares a day.

Over the past year Alpha Tau Medical has ranged from $3.43 to $15.79, and now sits 79% of the way up that range.

Alpha Tau Medical met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q2 FY26 it reported -$0.50 per share against an estimate of -$0.1438.

The average analyst price target is $18.16, 38.0% above the current price, from 5 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

80%of 5 analyst ratings say Buy
  • Buy80.0%
  • Hold20.0%
  • Sell0.0%
Price target · 7 analystsAvg $18.16
Low
$8.08
Now
$13.16
High
$31.50

DRTS earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 20.9% on average.

  1. Q3 FY24: reported -$0.10 per share against an estimate of -$0.1227
  2. Q4 FY24: reported -$0.13 per share against an estimate of -$0.1238
  3. Q1 FY25: reported -$0.12 per share against an estimate of -$0.1298
  4. Q2 FY25: reported -$0.13 per share against an estimate of -$0.1165
  5. Q3 FY25: reported -$0.14 per share against an estimate of -$0.1176
  6. Q4 FY25: reported -$0.08 per share against an estimate of -$0.126
  7. Q1 FY26: reported -$0.26 per share against an estimate of -$0.126
  8. Q2 FY26: reported -$0.50 per share against an estimate of -$0.1438

DRTS news

  • Press releaseGlobe Newswire

    Alpha Tau Completes Patient Enrollment in its Multicenter IMPACT Pancreatic Cancer Pilot Study of Alpha DaRT® Following Strong Demand and Multiple Expansions

  • Press releasePRNewswire

    Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet

  • 12 Health Care Stocks Moving In Monday's Intraday Session

  • Vandana Singh

    Alpha Tau Medical Stock Surges As Interim Brain Tumor Trial Data Sparks Rally

  • 12 Health Care Stocks Moving In Monday's Pre-Market Session

  • Press releaseGlobe Newswire

    Alpha Tau Announces FDA Approval of IDE Supplement to Expand Alpha DaRT® IMPACT Trial to Patients with Pancreatic Cancer Receiving Gemcitabine with Abraxane® (Nab-Paclitaxel)

  • 12 Health Care Stocks Moving In Wednesday's Pre-Market Session

  • Press releasePRNewswire

    Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical

Similar companies

Companies in the same industry as Alpha Tau Medical

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.